Prognostic Significance of MicroRNA-375 Downregulation in Solid Tumors: A Meta-Analysis

Table 2

The pooled associations between different situations of miR-375 expression and the prognosis of patients with solid tumors.

Outcome subgroup	Number of patients	Number of studies	HR (95% CI)	value	Heterogeneity
					Overall effect	1652	16	1.91 (1.48–2.45)^b	<0.001*	43.2	0.033
Tumor type
Esophageal carcinoma	781	8	2.24 (1.69–2.96)^a	<0.001*	1.9	0.415
NSCLC	313	3	1.71 (1.31–2.24)^a	<0.001*	0.0	0.554
Other cancers	558	5	1.59 (0.71–3.58)^b	0.26	74.5	0.004
miR-375 assay method
QRT-PCR	1403	15	1.88 (1.42–2.48)^b	<0.001*	46.2	0.026
MISH	249	1	1.99 (1.28–3.10)	0.002*
HR obtain method
Reported in text	894	8	1.97 (1.57–2.47)^a	<0.001*	10.8	0.346
Data extrapolated	758	8	1.58 (0.99–2.51)^b	0.054	61.6	0.011
Analysis type
Multivariate	894	8	1.97 (1.57–2.47)^a	<0.001*	10.8	0.346
Univariate	758	8	1.58 (0.99–2.51)^b	0.054	61.6	0.011
Source of miRNA
Tissue	1027	11	2.16 (1.73–2.71)^a	<0.001*	15.7	0.295
Blood	625	5	1.40 (0.84–2.35)^b	0.197	63.5	0.027
Patient origin
China	1087	9	1.96 (1.62–2.37)^a	<0.001*	5.7	0.388
USA	351	5	1.97 (1.30–2.99)^a	=0.001*	36.2	0.180
Other countries	214	2	0.58 (0.10–3.24)^b	0.534	50.7	0.154

NSCLC: non-small-cell lung cancer; qRT-PCR: quantitative real-time PCR; MISH: miRNA in situ hybridization; HR: hazard ratio; CI: confidence intervals.
*The difference was statistically significant.
^aFixed-effects model.
^bRandom-effects model.